rawpixel-shutterstock-com-5

Rawpixel / Shutterstock.com

29 October 2015Americas

Pfizer and Allergan merger talks at early stage

Pharmaceutical company Pfizer has confirmed it has entered into talks with generics company Allergan over a potential merger.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

AstraZeneca ‘has value’ says former Pfizer lawyer

28 April 2014 AstraZeneca’s portfolio does not appear to offer a long pipeline of marketed products with long periods of exclusivity, says Jason Rutt, head of the patents group at Rouse in London and former head of Pfizer’s UK patent department.

Biotechnology

Pfizer to collaborate with Imcyse on new immunotherapy programme

5 February 2021 Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides.

More on this story

AstraZeneca ‘has value’ says former Pfizer lawyer

28 April 2014 AstraZeneca’s portfolio does not appear to offer a long pipeline of marketed products with long periods of exclusivity, says Jason Rutt, head of the patents group at Rouse in London and former head of Pfizer’s UK patent department.

Biotechnology

Pfizer to collaborate with Imcyse on new immunotherapy programme

5 February 2021 Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides.

More on this story

AstraZeneca ‘has value’ says former Pfizer lawyer

28 April 2014 AstraZeneca’s portfolio does not appear to offer a long pipeline of marketed products with long periods of exclusivity, says Jason Rutt, head of the patents group at Rouse in London and former head of Pfizer’s UK patent department.

Biotechnology

Pfizer to collaborate with Imcyse on new immunotherapy programme

5 February 2021 Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York